Phi Therapeutics

Phi Therapeutics is a private microbiome-focused biotech company operating commercially through its Phyla skincare brand. The company develops bacteriophage-based, microbiome-editing products intended to selectively reduce acne-causing Cutibacterium acnes while preserving beneficial skin bacteria. Its lead commercial focus is acne, where it markets phage-based topical skincare products, and it has also described broader therapeutic interest in other skin disorders such as atopic dermatitis, rosacea, and cancer therapy-associated skin rash. Phi Therapeutics positions its core technology as an alternative to conventional antibiotics by using targeted phages rather than broad-spectrum bacterial killing. The business sits at the intersection of biotech, dermatology, and consumer health, with early non-dilutive and venture backing and a platform centered on precise subtraction of harmful microbes from the microbiome.